Navigation Links
New Pharmaceutical Company to Target Alzheimer's Disease
Date:10/21/2008

tients, caregivers and families," said Dr. Crawford. "We now have strategies to tackle the cause, not just the consequences, of Alzheimer's disease. We are confident that the expertise and dedication of the Archer staff will lead to effective treatments for this terrible disease."

A Phase I/IIA clinical trial, that is currently being conducted in Europe, was designed to evaluate the safety of Nilvadipine, the active ingredient of ARC029, in Alzheimer's sufferers. The study has shown that the drug was well tolerated in Alzheimer's patients.

While neither ARC029 nor ARC031 is currently available in the United States (U.S.), Archer Pharmaceuticals, Inc. is expecting to proceed with U.S. clinical studies within the next few months.

Archer Pharmaceuticals, Inc. intends to fast track ARC029 and ARC031, while continuing to work on other therapeutic approaches.

Archer Pharmaceuticals, Inc. is a fully independent health care company dedicated to enhancing and extending healthy human life. For more information or to invest in Archer Pharmaceuticals, Inc., please contact Geoff Birkett at (484) 467-1285 or visit http://www.ArcherPharma.com.


'/>"/>
SOURCE Archer Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
2. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
3. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
4. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
5. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
6. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
7. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
8. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
11. Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... BioPharma Have Entered into an Agreement Under, Which Genmab Will ... ... USA, COPENHAGEN, Denmark and REDWOOD CITY, California, February 21, ... ) announced today that they have entered into an agreement,under ...
... a,global provider of products and services that improve the ... by the New York,Department of Health for its public ... to maintain emergency response readiness, New,York has purchased more ... two years., Cardinal Health has already shipped 850 ...
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,that Dr. Mark Nestor ... Symposium in Miami., In his presentation to ... attributes of Pyratine-6(TM) for the treatment of,photodamaged skin ...
Cached Biology Technology:Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 2Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium 2Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium 3
(Date:7/14/2014)... Is cancer an inevitable consequence of aging? , Although ... consequence of aging, the risk of developing several common ... puzzled by the apparent decrease with age in the ... possible solution to this puzzle was presented in a ... by Professor James P. Brody of the Department ...
(Date:7/13/2014)... COLUMBUS, Ohio A new study in women suggests ... before eating a single high-fat meal can slow the ... questioned study participants about the previous day,s stressors before ... 60 grams of fat. The scientists then measured their ... to burn calories and fat and took measures ...
(Date:7/11/2014)... fires burning in eastern New South Wales, Australia when ... At 03:35 UTC on July 11 (12:35 p.m. local ... over eastern New South Wales (NSW), the Moderate Resolution ... of the region and spotted smoke (light brown) from ... bands, are outlined in red. , The New South ...
Breaking Biology News(10 mins):Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... June 5, 2012 /PRNewswire-iReach/ -- Global Information ... discounted registration for three important international healthcare and biotechnology ... Antibody Engineering Summit 2012 November 6 ... Annual Protein & Antibody Engineering Summit (PEGS Europe) presents ...
... Ph.D., Wellcome Trust Principal Research Fellow and Head, ... of Emmanuel College, Cambridge, has been bestowed the ... recognizing exemplary leadership in the international microbiological community. ... of Virginia, says Smith is "internationally recognized as ...
... (June 6, 2012) Two studies appearing in the ... freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , evaluate the ... pancreatic tissues, in addition to a clinical study that ... islets are better than cultured islets , A ...
Cached Biology News:Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information 2Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information 3The American Society for Microbiology honors Geoffrey L. Smith 2Some factors that impact islet transplantation explored in Cell Transplantation papers 2Some factors that impact islet transplantation explored in Cell Transplantation papers 3Some factors that impact islet transplantation explored in Cell Transplantation papers 4
...
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
...
Biology Products: